GNOM vs. IBB
Compare and contrast key facts about Global X Genomics & Biotechnology ETF (GNOM) and iShares Nasdaq Biotechnology ETF (IBB).
GNOM and IBB are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. GNOM is a passively managed fund by Global X that tracks the performance of the Solactive Genomics Index. It was launched on Apr 5, 2019. IBB is a passively managed fund by iShares that tracks the performance of the NASDAQ Biotechnology Index. It was launched on Feb 5, 2001. Both GNOM and IBB are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: GNOM or IBB.
Correlation
The correlation between GNOM and IBB is 0.61, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
GNOM vs. IBB - Performance Comparison
Key characteristics
GNOM:
-0.61
IBB:
-0.17
GNOM:
-0.72
IBB:
-0.09
GNOM:
0.92
IBB:
0.99
GNOM:
-0.26
IBB:
-0.10
GNOM:
-1.27
IBB:
-0.44
GNOM:
15.10%
IBB:
7.85%
GNOM:
31.47%
IBB:
21.07%
GNOM:
-75.00%
IBB:
-62.85%
GNOM:
-70.95%
IBB:
-29.32%
Returns By Period
In the year-to-date period, GNOM achieves a -16.58% return, which is significantly lower than IBB's -6.72% return.
GNOM
-16.58%
-4.37%
-22.78%
-16.41%
-11.69%
N/A
IBB
-6.72%
-6.04%
-12.81%
-1.68%
-0.20%
0.94%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
GNOM vs. IBB - Expense Ratio Comparison
GNOM has a 0.50% expense ratio, which is higher than IBB's 0.47% expense ratio.
Risk-Adjusted Performance
GNOM vs. IBB — Risk-Adjusted Performance Rank
GNOM
IBB
GNOM vs. IBB - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Global X Genomics & Biotechnology ETF (GNOM) and iShares Nasdaq Biotechnology ETF (IBB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
GNOM vs. IBB - Dividend Comparison
GNOM has not paid dividends to shareholders, while IBB's dividend yield for the trailing twelve months is around 0.31%.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
GNOM Global X Genomics & Biotechnology ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.04% | 0.14% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
IBB iShares Nasdaq Biotechnology ETF | 0.31% | 0.29% | 0.26% | 0.31% | 0.21% | 0.20% | 0.17% | 0.19% | 0.30% | 0.19% | 0.03% | 0.15% |
Drawdowns
GNOM vs. IBB - Drawdown Comparison
The maximum GNOM drawdown since its inception was -75.00%, which is greater than IBB's maximum drawdown of -62.85%. Use the drawdown chart below to compare losses from any high point for GNOM and IBB. For additional features, visit the drawdowns tool.
Volatility
GNOM vs. IBB - Volatility Comparison
Global X Genomics & Biotechnology ETF (GNOM) has a higher volatility of 17.01% compared to iShares Nasdaq Biotechnology ETF (IBB) at 12.76%. This indicates that GNOM's price experiences larger fluctuations and is considered to be riskier than IBB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.